HOME >> BIOLOGY >> NEWS
Muscle-targeted gene therapy reverses rare muscular dystrophy in mice

Durham, N.C. Gene therapy methods that specifically target muscle may reverse the symptoms of a rare form of muscular dystrophy, according to new research in mice conducted by medical geneticists at Duke University Medical Center. Infants born with the inherited muscular disorder called Pompe disease usually die before they reach the age of two. The researchers also said their approach of targeting corrective genes to muscles may have application in treating other muscular dystrophies.

Patients with Pompe disease have a defect in a key enzyme that converts glycogen, a stored form of sugar, into glucose, the body's primary energy source. As a result, glycogen builds up in muscles throughout the body, including the heart, causing muscles to degenerate.

Using genetically altered mice in which the gene for the enzyme had been rendered nonfunctional, the researchers demonstrated they could introduce the functioning gene and correct glycogen buildup in heart and skeletal muscle. The findings suggest that such an approach should be considered as a potential gene therapy strategy for Pompe disease patients, the researchers report in a forthcoming issue of Molecular Therapy (now available online).

"Gene therapy in muscular dystrophies presents a unique challenge, because replacement of deficient, therapeutic proteins invokes an immune response that limits the efficacy of the treatment," said Duke medical geneticist Dwight Koeberl, M.D., senior author of the study. "By restricting the expression of introduced genes to muscle, the immune response can be prevented or attenuated."

The muscle-targeted gene therapy might therefore apply to other forms of muscular dystrophy, they added. Muscular dystrophies include many genetic diseases, all of which are characterized by progressive weakness and degeneration of the skeletal muscles which control movement.

The Muscular Dystrophy Association and Genzyme Corporation supported the research.
'"/>

Contact: Kendall Morgan
kendall.morgan@duke.edu
919-660-1306
Duke University Medical Center
28-Mar-2005


Page: 1 2 3

Related biology news :

1. Testosterone replacement therapy: How safe for aging men?
2. Progesterone therapy and preterm birth: More evidence helps identify women who can benefit
3. Aggressive therapy best for certain AML patients
4. Under magnetic force, nanoparticles may deliver gene therapy
5. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
6. Stem cell therapy rescues motor neurons in ALS model
7. Study identifies new gene therapy tools for inherited blindness
8. Breast cancer and hormone therapy -- A looking-glass mirror?
9. Radiation therapy combined with microsurgery shows promise for curing injured spinal cord
10. Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer
11. Scientists follow familiar TRAIL to new cancer therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/14/2019)... ... August 14, 2019 , ... An upcoming episode ... in microbiome therapeutics are helping to promote normal immune function in order to ... will educate about the DECODE.DESIGN.CURE™ technology platform, which rapidly develops microbiome therapeutics in ...
(Date:8/14/2019)... ... , ... Gateway Genomics , a leading developer of direct-to-consumer genetic tests ... annual Inc. 500|5000 list of fastest growing private companies, in the first year ... and generating revenue by March 31, 2015. Ranking in the list is determined by ...
(Date:8/6/2019)... ... August 06, 2019 , ... ... modeling system that could have far-reaching implications for personalized medicine, especially when seeking ... (PLSR), is able to predict which stem cell donors and manipulation methods might ...
Breaking Biology News(10 mins):
(Date:6/18/2019)... ... June 17, 2019 , ... IVERIC bio, ... an agreement for production and manufacturing of GMP-grade adeno-associated virus (AAV) vector for ... dominant retinitis pigmentosa (RHO-adRP) and IC-200 for the treatment of BEST1 related retinal ...
(Date:6/11/2019)... ... June 10, 2019 , ... ... distribution network with the appointment of Biofeedback Tech Ltd as its ... are an essential part of many therapeutic treatments and clinical assessment protocols to ...
(Date:6/11/2019)... ... June 11, 2019 , ... Mytonomy, the ... national leader in opioid treatment, announced today they are partnering to combat the ... recently deployed its virtual care platform at the Mayo Clinic to drive shared ...
(Date:6/6/2019)... ... 05, 2019 , ... WCCT Global, Inc ., a full-service early phase ... they will be receiving 3 awards at the 2019 CRO Leadership Awards, to be ... the categories of overall Quality and Compatibility (Access to desired markets, cultural fit, timely ...
Breaking Biology Technology:
Cached News: